Neuronetics (NASDAQ:STIM – Get Free Report) released its earnings results on Tuesday. Here are the key takeaways from Neuronetics’ conference call:Get Neuronetics alerts:Revenue rose 9.1% to $41.6 million , while adjusted EBITDA improved to positive $0.3 million from negative $5.6 million a year ago. Neuronetics Stock PerformanceNeuronetics stock opened at $2.99 on Tuesday. Weiss Ratings restated a “sell (e+)” rating on shares of Neuronetics in a research note on Thursday, June 18th. Neuronetics Company Profile(Get Free Report)Neuronetics, Inc is a commercial?stage medical technology company that develops and markets non-invasive neuromodulation therapies for psychiatric and neurological disorders.